The purpose of this study is to evaluate the safety, tolerability, efficacy of 3 doses of CS1 (sodium valproate) Delayed-Release Capsules in the treatment of pulmonary arterial hypertension (PAH). The evaluation of CS1 will be done in patients with PAH who also have or are willing to use the CardioMEMS Heart Failure System. repeated measurements of PAP and other hemodynamic parameters.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Jimmy Ford
Medicine-Pulmonary
Clinical or Medical
Interventional
Chronic Conditions
Heart and Circulation
Lungs and Breathing
21-3020
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
